TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Completed · Phase 1/Phase 2

Conditions studied: Non-small Cell Lung Cancer

In brief

The purpose of this trial is to study the efficacy and safety of the combination of TLK286 with cisplatin as first-line therapy for patients with locally advanced or metastatic non-small cell lung cancer.

Key facts

Study ID

NCT00077883

Run by

Telik

People needed

50

Starts

2004-02-01

Expected to finish

2007-03-01

Last updated by the study team

2011-07-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or older
• Histologically confirmed non-small cell lung cancer
• Stage IV or IIIB
• Measurable disease by RECIST
• ECOG performance status of 0-1
• Adequate liver and renal function
• Adequate bone marrow reserve

You may not qualify if…

• History of bone marrow transplantation or stem cell support
• Pregnant or lactating women

Where it is running

• Univ. of MD, Greenbaum Cancer Center — Baltimore, Maryland, United States
• The Sarah Cannon Cancer Center — Nashville, Tennessee, United States
• Univ. of TX, MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.